Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Franchi

Showing results (61-70 of 147) with videos related to

Pageof 15
Sort By:
Minerva Cardiology and Angiology|October 23, 2023
Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapySalvatore Giordano, Francesco Franchi, Fabiana Rollini, et al.
Expert Review of Clinical Pharmacology|July 11, 2017
Role of genetic testing in patients undergoing percutaneous coronary interventionJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
International Journal of Cardiology|May 8, 2012
Effect of cardiac resynchronization therapy on left atrial reverse remodeling: role of echocardiographic AV delay optimizationAlessandro Malagoli, Luca Rossi, Francesco Franchi, et al.
Expert Review of Cardiovascular Therapy|November 3, 2023
Bivalirudin in acute coronary syndromesMattia Galli, Marco Bernardi, Luis Ortega-Paz, et al.
Drugs|July 29, 2024
Therapeutic Potential of FXI Inhibitors: Hype or Hope?Mattia Galli, Giovanni Occhipinti, Luis Ortega-Paz, et al.
Journal of the American College of Cardiology|February 13, 2016
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCIDominick J Angiolillo, Francesco Franchi, Ron Waksman, et al.
Thrombosis and Haemostasis|October 10, 2025
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled StudiesLuis Ortega-Paz, Yasushi Ueki, Claudio Laudani, et al.
Expert Review of Clinical Pharmacology|December 1, 2022
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implicationsMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Minerva Cardiology and Angiology|November 11, 2021
Dual pathway inhibition in atherothrombosis prevention: yes, now we can!Francesco Summaria, Giuseppe Biondi-Zoccai, Enrico Romagnoli, et al.
JACC. Cardiovascular Interventions|July 8, 2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y<sub>12</sub> Receptor-Mediated Signaling in Ticagrelor-Treated PatientsFabiana Rollini, Francesco Franchi, Estela Thano, et al.
Pageof 15

Showing results (61-70 of 147) with videos related to

Sort By:
Pageof 15
Minerva Cardiology and Angiology|October 23, 2023
Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapySalvatore Giordano, Francesco Franchi, Fabiana Rollini, et al.
Expert Review of Clinical Pharmacology|July 11, 2017
Role of genetic testing in patients undergoing percutaneous coronary interventionJae Youn Moon, Francesco Franchi, Fabiana Rollini, et al.
International Journal of Cardiology|May 8, 2012
Effect of cardiac resynchronization therapy on left atrial reverse remodeling: role of echocardiographic AV delay optimizationAlessandro Malagoli, Luca Rossi, Francesco Franchi, et al.
Expert Review of Cardiovascular Therapy|November 3, 2023
Bivalirudin in acute coronary syndromesMattia Galli, Marco Bernardi, Luis Ortega-Paz, et al.
Drugs|July 29, 2024
Therapeutic Potential of FXI Inhibitors: Hype or Hope?Mattia Galli, Giovanni Occhipinti, Luis Ortega-Paz, et al.
Journal of the American College of Cardiology|February 13, 2016
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCIDominick J Angiolillo, Francesco Franchi, Ron Waksman, et al.
Thrombosis and Haemostasis|October 10, 2025
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled StudiesLuis Ortega-Paz, Yasushi Ueki, Claudio Laudani, et al.
Expert Review of Clinical Pharmacology|December 1, 2022
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implicationsMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Minerva Cardiology and Angiology|November 11, 2021
Dual pathway inhibition in atherothrombosis prevention: yes, now we can!Francesco Summaria, Giuseppe Biondi-Zoccai, Enrico Romagnoli, et al.
JACC. Cardiovascular Interventions|July 8, 2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y<sub>12</sub> Receptor-Mediated Signaling in Ticagrelor-Treated PatientsFabiana Rollini, Francesco Franchi, Estela Thano, et al.
Pageof 15